Breaking the Biosimilar Bottleneck

The Food and Drug Administration (FDA) released draft guidance that could dramatically boost biosimilar development. The draft guidance offers a smoother regulatory pathway that would speed regulatory approvals and lower costs for payers, plans, and patients. 

At the same time, the federal agency is proposing to drop the long-standing requirement to run large clinical comparative-efficacy trials for many biosimilars. 

Together, these developments mark a strategic shift to create a streamlined path to get more biosimilars to market. 

Deeper dive into the proposed changes

The new draft guidance, titled, “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies,” states that if a proposed biosimilar is manufactured under highly controlled conditions, with a well-characterized reference product, the FDA concludes that a Comparative Analytical Assessment (CAA) plus pharmacokinetic/immunogenicity data may suffice—and a full clinical comparative efficacy study (CES) may not be required. 

The guidance also signals the agency’s preference to generally avoid “switching studies” (studies in which patients move from reference biologic to biosimilar) as part of interchangeability determinations. 

The FDA notes that CESs historically take 1–3 years and average ~$24 million in cost, so these changes would mean shorter time to market, lower development cost, more competition in biologics space, and ultimately lower drug costs for payers, plans and patients. 

Changes will help drug costs

For plan sponsors and insurers (including employers and Medicaid/Medicare plans), greater biosimilar availability means a potential leverage point to reduce spend on high-cost biologics. Biologics account for only ~5% of prescriptions in the U.S. but ~51% of drug spend. 

For pharmaceutical sponsors (including biosimilar developers), reduced trial burdens and cost barriers make biosimilar development more commercially viable, and more attractive as a business opportunity.

For providers and patients, improved access to lower-cost biologic alternatives (assuming adoption and formulary uptake) could expand treatment options and relieve cost pressure.

Addressing the Uptake Gap and Market Reality

Despite regulatory frameworks existing since the Biologics Price Competition and Innovation Act (BPCIA) of 2010, the biosimilar market in the U.S. has grown far slower than expected. The FDA has approved 76 biosimilars so far (as of this guidance) whereas generics number in the tens of thousands. 

The key barriers to biosimilar development and adoption:

• High development cost and long regulatory timelines
• Market and contracting dynamics: originator biologic manufacturers and patent/settlement strategies have all limited competitive biosimilar launch. 
• Provider/patient hesitancy and lower awareness: biologics and biosimilars are more complex than simple chemical generics and trust plays a role.
• Delayed interchangeability and substitution uptake: even when biosimilars are approved, formulary adoption, reimbursement positioning, and product listing tend to lag.

The new FDA actions aim to address the foundational “supply-side” barrier (approval/timeline/cost), which is necessary but not sufficient to address full adoption. Market access and behavioral factors remain.

Our strategic advice for stakeholders:

For Plan Sponsors/Multi-State Governments/Medicaid

1. Monitor biosimilar launches of key biologics (especially those losing exclusivity) and proactively plan for biosimilar migration when available.
2. Ensure formularies, medical benefit contracting, and provider network incentives are aligned to support biosimilar uptake.
3. Build educational strategies (for providers and members) to increase comfort with biosimilars, especially if ABM/member-experience is emphasized.
4. Take advantage of the regulatory momentum: faster biosimilar development may increase competition and thus leverage in contracting.

For Providers/Physicians

1. Stay informed about biosimilar safety, interchangeability, and regulatory changes. The regulatory paradigm is shifting from requiring large human trials to relying more on analytical equivalence.
2. Consider instituting protocols or EMR flags for biosimilar substitution when available, aligned with clinical evidence and payer models.

In an era of cost escalation and value-based care, biosimilar adoption can align with physician-directed cost-conscious prescribing while maintaining quality.

Our Take: Risks and Open Questions

• The analytic-only pathway may not fit every case. The FDA’s draft guidance acknowledges that some biologics, such as locally acting products, may still require comparative efficacy studies.
• Provider and patient confidence will determine real-world success. Regulatory approval is only part of the equation; widespread adoption depends on education, trust, and a shift in clinical behavior.
• Payer and PBM incentives must align with biosimilar adoption. Contracting and rebate structures currently favor originator biologics, hence faster approvals alone will not drive meaningful uptake. Solutions like RazorMetrics can dramatically help with biosimilar adoption.

The FDA’s new guidance offers a significant helping hand to biosimilars. Lowering the regulatory hurdles by eliminating or reducing major clinical trials will change the biosimilar market. While the changes will build momentum for biologic drug competition, the potential savings still depend on plan sponsors, physicians, and patients to adopt the less expensive alternative.

The full value of biosimilars will only materialize when market access, contracting, provider behavior and member experience are in alignment. For plan sponsors, government programs, biosimilar developers and providers, this is an opportunity to embed biosimilars more fully into their cost-management and clinical value frameworks.

RazorMetrics’ Approach to Biosimilars

RazorMetrics identifies clinically appropriate biosimilar options within a physician’s normal workflow—no disruption, no extra steps. Our analytics surface safe, lower-cost alternatives for high-spend biologics, allowing prescribers to review and approve switches before any member outreach occurs. Our physician-directed approach accelerates biosimilar adoption, supports plan-sponsor savings, and preserves provider trust.